Proxy Votes Now

Home › Activist investors › Camac Fund, LP

Camac Fund, LP

Dissident not on the roster. Positions and campaigns from Camac Fund, LP’s SEC filings. Updated November 20, 2026.

Filer entities
Camac Fund, LP
SEC CIK
1516478 (Camac Fund, LP)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
0current positions
0new or changed in 90 days
0active campaigns
1campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (0)

No current position by this definition.

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (1)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Forte Biosciences, Inc.Board seats Contested vote held — 0 of 2 of the activist's nominees elected Sep 19, 2023 May 25, 2023 Proxy contest filed latest (8) how managers voted

How large managers voted in Camac Fund, LP’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

Contested director elections at which Camac Fund, LP had nominees on the ballot, from the managers’ N-PX vote reports and the company’s Form 8-K (Item 5.07) results. A manager “backed” a side when most of its funds’ votes on that side’s nominees were FOR; with a universal proxy card a fund can vote for nominees of both sides, so the counts are shown too.

Top 5 managers across 1 contest

ManagerBacked the activistForte Biosciences, Inc.
2023
Vanguard0 of 1 (0%) Company
Fidelity0 of 1 (0%) Split
BlackRock0 of 1 (0%) Company
Blackstone Alternative Investment Funds0 of 1 (0%) Split
Guggenheim0 of 1 (0%) Split

— = no N-PX votes on the contested director elections found for that manager.

Forte Biosciences, Inc. · meeting Sep 19, 2023 · 0 of 2 of the activist’s nominees elected

Result: Form 8-K, Item 5.07. Activist’s nominees: Chris McIntyre (not elected (8-k tally)); Michael G. Hacke (not elected (8-k tally)). Company’s nominees: Lawrence Eichenfield, M.D. (elected (8-k tally)); Paul A. Wagner, Ph.D. (elected (8-k tally)).

ManagerStanceFOR the activist’s nomineesAvg. shares FOR each activist nomineeFOR the company’s nominees
Vanguard Backed the company's nominees 0 of 6 fund votes 0 6 of 6 fund votes
Fidelity Split 4 of 8 fund votes 100,798 0 of 4 fund votes
BlackRock Backed the company's nominees 0 of 2 fund votes 0 2 of 2 fund votes
Blackstone Alternative Investment Funds Split 1 of 2 fund votes 400 0 of 1 fund votes
Guggenheim Split 1 of 2 fund votes 34 0 of 1 fund votes

Source: N-PX reports filed by 5 managers for the meeting of Sep 19, 2023; a nominee’s side is read from how most filers labelled the ballot item (two or more filers, 70% agreeing).

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

1Contest vote: nominees not elected
Outcome of each campaign (1)
CompanyOutcomeDetailDateFirst filing
Forte Biosciences, Inc. Contest vote: nominees not elected 0 of 2 of the activist's nominees elected Sep 19, 2023 May 25, 2023

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 0 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.